Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 4/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | THRA | P10827 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 4/20 | 0.35 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19449792 | 0.84 | EPHX2 (0.41) | KMT2AHDAC1HDAC6ALDH1A1POLB | |
| SCHEMBL28470841 | 0.84 | ALDH1A1 (0.52) | KMT2AALDH1A1POLBMAPTRAB9A | |
| SCHEMBL19435750 | 0.82 | CA1 (0.48) | KMT2AHDAC1HDAC6ALDH1A1POLB | |
| SCHEMBL27577346 | 0.82 | LOXL2 (0.53) | KMT2AHDAC1HDAC6LOXL2 | |
| SCHEMBL28466726 | 0.81 | PLK1 (0.54) | KMT2AALDH1A1POLBMAPTRAB9A | |
| SCHEMBL19435693 | 0.79 | MAPT (0.45) | KMT2AALDH1A1MAPTRAB9AACACB | |
| SCHEMBL28466232 | 0.78 | PLK1 (0.57) | KMT2AALDH1A1POLBTHRATHRB | |
| SCHEMBL7733506 | 0.77 | ALDH1A1 (0.48) | KMT2AHDAC1HDAC6ALDH1A1MAPT | |
| SCHEMBL19724896 | 0.77 | CA1 (0.47) | KMT2AALDH1A1MAPTRAB9ALMNA | |
| SCHEMBL28460406 | 0.77 | THRA (0.63) | KMT2AALDH1A1MAPTTHRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170291885-A1 | METHOD FOR PREPARING ENAMIDE COMPOUND AND RUTHENIUM COMPLEX CATALYST USED THEREIN | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2017-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291885-A1 | METHOD FOR PREPARING ENAMIDE COMPOUND AND RUTHENIUM COMPLEX CATALYST USED THEREIN | ENY2, ENO1, IDH1 | KMT2A 545/4885IDO1 358/4885HDAC1 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.